肿瘤基质比（TSR）已在许多肿瘤类型中进行了分析。到目前为止，TSR在咽喉鳞状细胞癌（OPSCC）的临床意义尚未得到研究。我们在赫尔辛基大学医院治疗的182名OPSCC患者中使用了最近推荐的TSR评估方法。在紫红染色（HE）的切片中估计了与肿瘤相关的基质的百分比，并分为两组：“基质高”（>50%）和“基质低”（≤50%）。多元分析中，TSR与患者生存率有显着关联，因为基质高的肿瘤表现出较差的无病生存率（HR 3.22，95％CI 1.43-7.26，P = 0.005），疾病特异性生存率（HR 2.48，95％CI 1.29-4.74，P = 0.006）和总生存率（HR 2.23，95％CI 1.29-3.85，P = 0.004）。TSR的预后价值优于TNM分类。此外，当分别分析HPV阳性和HPV阴性病例时，TSR的显著预后价值也得到了证明（P <0.05）。总之，TSR是OPSCC的强有力预后指标。使用标准HE切片可以快速评估，而不需要额外费用。由于其简单性和可重复性，TSR可在常规病理诊断和报告中实施。基质丰富的肿瘤患者具有更高的复发和癌症相关死亡风险，并可能受益于适当的强化治疗策略和密切的随访。版权所有©2023作者。Elsevier Inc.发表。保留所有权利。

Tumor-stroma ratio (TSR) has been analyzed in many tumor types. To date, the clinical significance of TSR has not been investigated in oropharyngeal squamous cell carcinoma (OPSCC). We used a recently introduced recommendation for the assessment of TSR in a large cohort of 182 OPSCC patients treated at the Helsinki University Hospital. The percentage of tumor-associated stroma was estimated in hematoxylin and eosin (HE)-stained sections and categorized into two groups: "stroma-high" (>50%) and "stroma-low" (≤50%). In multivariable analysis, TSR had a significant association with patient survival as stroma-high tumors showed a worse disease-free survival (HR 3.22, 95%CI 1.43-7.26, P = 0.005), disease-specific survival (HR 2.48, 95% CI 1.29-4.74, P = 0.006), and overall survival (HR 2.23, 95% CI 1.29-3.85, P = 0.004). The prognostic value of TSR was superior to TNM classification. In addition, the significant prognostic value of TSR was demonstrated when analyzing HPV-positive and HPV-negative cases separately (P < 0.05). In conclusion, TSR is a powerful prognostic indicator in OPSCC. It can be assessed quickly without additional costs using standard HE slides. Due to its simplicity and reproducibility, TSR can be implemented in routine pathology diagnostics and reporting. Patients with stroma-rich tumors have an increased risk of recurrence and cancer-related mortality and may benefit from appropriate intensive treatment strategies with close follow-up.Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.